Analysis – Page 36 – Goldea Capital

MT Højgaard Holding A/S: Consolidation and strengthening of order portfolio in Q2

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

SECOND-QUARTER RESULTS (Comparative figures for the second quarter of 2024 are shown in brackets) The second quarter was characterised by high production and a significant intake of new orders. Revenue and operating profit developed in line with the full-year expectations, and profit after tax improved following the winding-up of loss-making international activities.Revenue amounted to DKK 2,675 million (DKK 2,665 million), Enemærke & Petersen recorded growth, while MT Højgaard Danmark experienced a slight decline in activity due to quarter-on-quarter fluctuations. The gross margin improved, driven by MT Højgaard Danmark, while a number of projects continued to weigh on Enemærke & Petersen’s margin. The operating profit (EBIT) of DKK 100 million (DKK 124 million) was affected by investments in capacity building and losses...

Interim Financial Report, H1 2025

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

Jyske Realkredit A/S – Interim Financial Report, H1 2025 To NASDAQ Copenhagen A/S 19 August 2025 Announcement No. 67/2025 Interim Financial Report, H1 2025 On August 19, 2025, the Supervisory Board has approved the Interim Financial Report, H1 2025 of Jyske Realkredit A/S. Please see the attached file. Yours sincerely,Jyske Realkredit A/S Anders Lund HansenCEO Direct phone (+45) 89 89 92 20E-mail: alh@jyskerealkredit.dk Web: jyskerealkredit.dk Please observe that the Danish version of this announcement prevails. Attached files:Interim Financial Report of Jyske Realkredit H1 2025.pdfAttachment...

Interim Financial Report, H1 2025

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

Expected net profit in 2025 specified at the upper end of DKK 3.8bn-4.6bn, equivalent to earnings per share at the upper end of DKK 60-73 Earnings per share at DKK 39.4 (H1 2024: DKK 38.8) Core income at DKK 6,503m (H1 2024: DKK 6,828m) Core expenses at DKK 3,195m (H1 2024: DKK 3,160m) Loan impairment charges: income of DKK 47m (H1 2024: expense of DKK 95m) Management’s estimate relating to loan impairment charges at DKK 1,877m (end of 2024: DKK 1,782m) Capital ratio at 21.5%, of which common equity tier 1 capital ratio at 16.3% (H1 2024: 21.9% and 16.6%, respectively)Summary ”Overall, we are seeing good activity and have refined our outlook. Over the past year, Jyske Bank significantly improved customer satisfaction among both personal and corporate customers and was named “Best at Private Banking” for the tenth year running....

Coloplast A/S – Interim Financial Report, 9M 2024/25

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment.Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant...

41/2025・Trifork Group: Interim report for the quarter and half-year ending 30 June 2025

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

Company announcement no. 41/2025Schindellegi, Switzerland – 19 August 2025 Interim Financial Report for the three and six months ending 30 June 2025 Trifork Group reports Q2 revenue growth of 5.1% driven by good progress in products and the public sector CEO Jørn Larsen comments: “Considering the difficult business climate our private customers currently operate in, Q2 continued the solid trend from Q1 from a business development perspective. It is encouraging to see our business units working together, both locally and cross-border, to strengthen our product- and solution-driven go-to-market approach. This is beginning to be reflected in our numbers. In the first half of 2025, our product-based segment, Run, grew revenue by 59.4% and accounted for 33.6% of total revenue. Revenue from our in-house IP grew by 25.8%, supported by increased...

Scatec second quarter 2025: Strong financial performance with continuing growth momentum

Written by Customer Service on August 19, 2025. Posted in Earnings Releases And Operating Results.

Oslo, 19 August 2025: In the second quarter, Scatec delivered solid financial results and achieved several strategic milestones, reinforcing its position as a leading provider of renewable energy in high-growth markets. Proportionate revenues increased by 51% to NOK 2,302 million (1,528 million), and EBITDA rose by 19% to NOK 1,130 million (951 million). Power production revenues were NOK 1,312 million (1,045 million) and EBITDA NOK 1,110 million (873 million), mainly driven by strong performance in the Philippines, including a retroactive effect of 231 million from official approval of the awarded ancillary services contract rates. Total power production from Scatec’s power plants ended at 940 GWh (995 GWh). “We continue to deliver strong financial results across all segments, while adding quality projects to our backlog and further strengthening...

Basilea on track with strong 2025 half-year results

Written by Customer Service on August 19, 2025. Posted in Public Companies.

Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating cash flow increases by 29% to CHF 23.1 million Full-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibioticAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the first half-year ended June 30, 2025. David Veitch, Chief Executive Officer, stated: “The first half of 2025 has marked a period of strong execution and meaningful progress across both...

40/2025・Trifork Group AG and key employees divest 51% of Trifork Security A/S to Wingmen Solutions ApS

Written by Customer Service on August 19, 2025. Posted in Public Companies.

Company announcement no. 40 / 2025Schindellegi, Switzerland – 19 August 2025 Trifork Group AG and key employees divest 51% of Trifork Security A/S to Wingmen Solutions ApS As previously communicated, Trifork Group AG has been seeking a long-term business partner for the Danish subsidiary Trifork Security A/S to accelerate its managed security services offering in Denmark and abroad. Today, an agreement has been signed with Wingmen Solutions ApS, a company owned by Springboard Network BV and ultimately owned by its management, employees, and Quadrum Capital BV, concerning the sale of 51.0% of the share capital of Trifork Security A/S. Strategic rationale Trifork Security A/S operates primarily in Denmark and is a leading specialist in managed services, offering solutions for log management, cybersecurity, and observability based on...

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

Written by Customer Service on August 19, 2025. Posted in Public Companies.

SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), as the sales agent. Pursuant to the Sales Agreement, the Company may offer and sell through the Agent, ordinary shares, no par value (the “Shares”), of the Company having an aggregate value of up to U.S.$4,304,945. The timing and amount of any sales of Shares under the ATM program will be determined by the Company at its discretion, depending...

Traction Uranium Corp. Appoints Paul Sparkes as Director

Written by Customer Service on August 19, 2025. Posted in Public Companies.

CALGARY, Alberta, Aug. 18, 2025 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (OTC: TRCTF) (FRA: Z1K) (the “Company” or “Traction”) is pleased to announce the appointment of Paul Sparkes as Director of the Company. Mr. Sparkes is an accomplished business leader and entrepreneur with over twenty-five years of experience in media, finance, capital markets and Canada’s political arena. Mr. Sparkes spent a decade as a leader in the broadcast and media industry as CTV Globemedia’s Executive Vice President, Corporate Affairs. He also held senior positions in public service, including with the Government of Canada as Director of Operations to Prime Minister, Jean Chretien, and as a senior aide to two Premiers of Newfoundland and Labrador. Mr. Sparkes was a Co-Founder and executive vice chairman at Difference Capital Financial...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals